Skip to results

Keyword or reference number

Keyword or reference number

Expected publication date

Expected publication date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 226 to 250 of 392

Guidance, NICE advice and quality standards in development
TitleTypeExpected publication date
Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]Technology appraisal guidanceTBC
Nivolumab with ipilimumab for untreated unresectable stage 3 non-small-cell lung cancer [ID6248]Technology appraisal guidanceTBC
Non-alcoholic fatty liver disease (NAFLD): assessment and managementNICE guidelineTBC
Non-invasive skin closure devices for surgical incisions (MT775)Medical technologies guidanceTBC
Nusinersen and risdiplam for treating spinal muscular atrophy (review of TA588 and TA755) [ID6195]Technology appraisal guidanceTBC
NY-ESO-1 T-cells for treating synovial sarcoma ID1286Technology appraisal guidanceTBC
Obecabtagene autoleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia [ID6347]Technology appraisal guidance
Obeticholic acid for treating liver fibrosis in people with steatohepatitis [ID1645]Technology appraisal guidanceTBC
Odevixibat for treating cholestasis and pruritus in Alagille Syndrome [ID6181]Technology appraisal guidanceTBC
Olaparib for treating BRCA mutation-positive HER2-negative metastatic breast cancer after chemotherapy (Review of TA762) [ID6336]Technology appraisal guidanceTBC
Olaparib with cediranib for treating platinum-resistant recurrent ovarian cancer after 1 or 2 therapies [ID4065]Technology appraisal guidanceTBC
Olipudase alfa for treating Niemann-Pick disease types A and B [ID3913 ]Highly specialised technologyTBC
Omaveloxolone for treating Friedreich's ataxia in people 16 years and over ID6423Technology appraisal guidance
Omburtamab for treating relapsed neuroblastoma [ID1664]Technology appraisal guidanceTBC
One-piece closed bags for adults with a colostomy: Late Stage AssessmentHealth technology evaluationTBC
Optical Coherence Tomography to guide percutaneous coronary interventionInterventional procedures guidanceTBC
Oral paclitaxel with encequidar for treating advanced breast cancer [ID5111]Technology appraisal guidanceTBC
OrganOx metra for liver transplant [ID5116]Technology appraisal guidanceTBC
Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection (Review of TA761) [ID5120]Technology appraisal guidanceTBC
Osimertinib for maintenance treatment of EGFR mutation-positive locally advanced unresectable non-small-cell lung cancer after platinum-based chemoradiation [ID6223]Technology appraisal guidance
Osimertinib with pemetrexed and platinum-based chemotherapy for untreated EGFR mutation-positive advanced non-small-cell lung cancer [ID6328]Technology appraisal guidanceTBC
Osteoporosis: risk assessment, treatment, and fragility fracture prevention (update)NICE guidelineTBC
Overweight and obesity managementNICE guidelineTBC
Oxybutynin hydrochloride for managing neurogenic detrusor overactivity in people 6 years and over with spinal cord injury or spina bifida [ID5089]Technology appraisal guidanceTBC
Palbociclib with trastuzumab and endocrine therapy for maintenance treatment of hormone-receptor positive, HER2-positive metastatic breast cancer [ID6251]Technology appraisal guidanceTBC

Results per page

  1. 10
  2. 25
  3. 50
  4. All